药物研发外包市场:现状分析与预测(2022-2030年)

由于癌症、CVD和罕见病等疾病的增加，药物发现外包市场预计将以7%左右的速度稳定增长。此外，新药开发需要各种专业技术和技能，例如基因组学、蛋白质组学和生物信息学。通过外包这些服务，製药公司可以利用更广泛的专业知识和技术来开发更多创新和有效的药物。

为了更好地了解药物发现外包行业的市场实施情况，市场分为北美（美国、加拿大、北美其他地区）、欧洲（德国、英国、法国、西班牙、意大利、欧洲其他地区）、亚洲太平洋地区（中国、日本、印度、亚太地区其他地区）以及世界其他地区（基于其全球影响力）。预计亚太地区在预测期内将以显着的复合年增长率增长。这是由于其人口众多以及遗传问题和疾病的高患病率。此外，这些国家拥有有利的监管环境，尤其是中国和印度，拥有低成本的熟练劳动力和高质量的数据，这将推动该市场的增长。

目录

第1章 市场简介

• 市场定义
• 主要目的
• 相关利益者
• 限制事项

第2章 调查手法或前提

• 调查流程
• 调查手法
• 受访者简介

第3章 市场摘要

第4章 摘要整理

第5章 COVID-19对药物研发外包市场带来的影响

第6章 药物研发外包的市场收益，2020-2030年

第7章 市场洞察:各类型

• 医药化学服务
• 生物学服务

第8章 市场洞察:药物类别

• 低分子
• 高分子(生物医药品)

第9章 市场洞察:各治疗领域

• 肿瘤学
• 感染疾病
• 呼吸疾病
• 循环系统
• 消化器官
• 其他

第10章 市场洞察:各地区

• 北美
  • 美国
  • 加拿大
  • 其他北美地区
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 全球其他地区

第11章 药物研发外包市场动态

• 推动市场要素
• 市场课题
• 影响分析

第12章 药物研发外包市场机会

第13章 药物研发外包市场趋势

第14章 需求面和供给面的分析

• 需求面分析
• 供给面分析

第15章 价值链分析

第16章 价格分析

第17章 策略性洞察能力

第18章 竞争模式

• 竞争情形
  • 波特的五力分析

第19章 企业简介

• Curia Global, Inc.
• Laboratory Corporation of America(R)Holdings
• Genscript
• Thermo Fisher Scientific Inc.
• Charles River Laboratories
• WuXi AppTec
• Merck & Co., Inc.
• Qiagen
• Jubilant Biosys Ltd.
• Eurofins DiscoverX Product

第20章 免责声明

Drug discovery outsourcing is the practice of outsourcing various stages of the drug discovery process to specialized service providers and contract research organizations (CROs). This includes services such as target identification and validation, lead generation and optimization, preclinical development, and clinical trials. By outsourcing drug discovery services, pharmaceutical companies can access specialized expertise, advanced technologies, and cost-effective solutions to accelerate drug development timelines and reduce R&D costs. The drug discovery outsourcing market is expected to continue growing in the coming years, driven by increasing demand for innovative and effective drugs, rising R&D costs, and a shortage of in-house resources.

The drug discovery outsourcing market is expected to grow at a steady rate of around 7% owing to the increasing cases of diseases such as cancer, CVD, and other rare diseases. Moreover, developing a new drug requires a range of specialized skills and technologies, including expertise in genomics, proteomics, and bioinformatics. By outsourcing these services, pharmaceutical companies can access a wider range of expertise and technologies, allowing them to develop more innovative and effective drugs. For instance, Charles River Laboratories International, Inc. and Valence Discovery announced a strategic partnership in April 2021 to accelerate preclinical drug discovery efforts and give customers access to Valence's artificial intelligence platform for molecular property prediction and generative chemistry.

Based on type, the drug discovery outsourcing market is segmented into medical chemistry service and biology service. The finished goods segment accounted for a significant market share in 2020 and it is estimated that it will grow rapidly during the projected timeframe. This is mainly due to these services providing essential services such as lead optimization, hit-to-lead (H2L) identification, and synthetic route scouting. Also, enable pharmaceutical companies to accelerate the drug discovery process and bring innovative drugs to the market faster.

Based on drug type, the drug discovery outsourcing market is segmented into small molecule and large molecules (biopharmaceuticals). The large molecules category is expected to grow at the fastest CAGR due to the growing number of drug and product approvals globally which is further attributed to increasing funding and investment by major key players or other biopharmaceutical companies to develop biologics & biosimilars.

Based on therapeutic area, the market is fragmented into oncology, infectious disease, respiratory disease, cardiovascular, gastrointestinal, and others. The oncology segment grabbed a considerable market share, and it is expected to grow at the fastest CAGR during the forecast period. This is mainly due to the increasing focus on the identification of novel targets to support cancer treatment and the growing number of patients with various types of cancer and the increasing number of elderly population will contribute to the growth of the market. For instance, according to the World Health Organization (WHO), there were an estimated 18.1 million new cases of cancer worldwide in 2020.

For a better understanding of the market adoption of the drug discovery outsourcing industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. APAC is anticipated to grow at a substantial CAGR during the forecast period. This is because of highly populated nations along with the high prevalence rate of genetic problems and diseases. Additionally, these nations have favorable regulatory environments and the availability of low-cost skilled labor and high-quality data, particularly in China and India, which will drive the growth of this market.

Some of the major players operating in the market include: Curia Global, Inc.; Laboratory Corporation of America® Holdings; Genscript; Thermo Fisher Scientific Inc.; Charles River Laboratories; WuXi AppTec; Merck & Co., Inc.; Qiagen; Jubilant Biosys Ltd.; Eurofins DiscoverX Products

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Drug Discovery Outsourcing Market
• 2.2. Research Methodology of the Drug Discovery Outsourcing Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE DRUG DISCOVERY OUTSOURCING MARKET

6 DRUG DISCOVERY OUTSOURCING MARKET REVENUE, 2020-2030F

7 MARKET INSIGHTS BY TYPE

• 7.1. Medical Chemistry Service
• 7.2. Biology Service

8 MARKET INSIGHTS BY DRUGS TYPE

• 8.1. Small Molecule
• 8.2. Large Molecules (Biopharmaceuticals)

9 MARKET INSIGHTS BY THERAPEUTIC AREA

• 9.1. Oncology
• 9.2. Infectious Disease
• 9.3. Respiratory Disease
• 9.4. Cardiovascular
• 9.5. Gastrointestinal
• 9.6. Others

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. U.K.
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Rest of Asia-Pacific
• 10.4. Rest of World

11 DRUG DISCOVERY OUTSOURCING MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 DRUG DISCOVERY OUTSOURCING MARKET OPPORTUNITIES

13 DRUG DISCOVERY OUTSOURCING MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

• 14.1. Demand Side Analysis
• 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 PRICING ANALYSIS

17 STRATEGIC INSIGHTS

18 COMPETITIVE SCENARIO

• 18.1. Competitive Landscape
  • 18.1.1. Porters Fiver Forces Analysis

19 COMPANY PROFILED

• 19.1. Curia Global, Inc.
• 19.2. Laboratory Corporation of America® Holdings
• 19.3. Genscript
• 19.4. Thermo Fisher Scientific Inc.
• 19.5. Charles River Laboratories
• 19.6. WuXi AppTec
• 19.7. Merck & Co., Inc.
• 19.8. Qiagen
• 19.9. Jubilant Biosys Ltd.
• 19.10. Eurofins DiscoverX Product

20 DISCLAIMER